AVBPEarnings•globenewswire•
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
Sentiment:Negative (20)
Summary
NEWTOWN SQUARE, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent Company progress.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by globenewswire